MCID: BRN056
MIFTS: 60

Bronchopulmonary Dysplasia

Categories: Fetal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchopulmonary Dysplasia

MalaCards integrated aliases for Bronchopulmonary Dysplasia:

Name: Bronchopulmonary Dysplasia 39 77 54 60 56 64 74
Bpd 54 60

Characteristics:

Orphanet epidemiological data:

60
bronchopulmonary dysplasia
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal; Age of death: normal life expectancy;

Classifications:



Summaries for Bronchopulmonary Dysplasia

PubMed Health : 64 About bronchopulmonary dysplasia: Bronchopulmonary (BRONG-ko-PUL-mo-NAR-e) dysplasia (dis-PLA-ze-ah), or BPD, is a serious lung condition that affects infants. BPD mostly affects premature infants who need oxygen therapy (oxygen given through nasal prongs, a mask, or a breathing tube).Most infants who develop BPD are born more than 10 weeks before their due dates, weigh less than 2 pounds (about 1,000 grams) at birth, and have breathing problems. Infections that occur before or shortly after birth also can contribute to BPD.Some infants who have BPD may need long-term breathing support from nasal continuous positive airway pressure (NCPAP) machines or ventilators.

MalaCards based summary : Bronchopulmonary Dysplasia, also known as bpd, is related to bronchial disease and chorioamnionitis. An important gene associated with Bronchopulmonary Dysplasia is SCGB1A1 (Secretoglobin Family 1A Member 1), and among its related pathways/superpathways are G-protein signaling RAC1 in cellular process and Immune response IFN alpha/beta signaling pathway. The drugs RespiGam and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include Lung and Lung, and related phenotypes are emphysema and respiratory distress

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 70589Disease definitionBronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring.Visit the Orphanet disease page for more resources.

Wikipedia : 77 Bronchopulmonary dysplasia (BPD; formerly chronic lung disease of infancy) is a chronic lung disease in... more...

Related Diseases for Bronchopulmonary Dysplasia

Diseases related to Bronchopulmonary Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 bronchial disease 31.6 CXCL8 ELANE RNASE3
2 chorioamnionitis 30.5 CXCL8 ELANE FLT1 IL1RN
3 newborn respiratory distress syndrome 30.5 CXCL8 ELANE SCGB1A1 SFTPB
4 lung disease 30.5 CXCL8 ELANE RNASE3 SFTPB
5 pneumonia 30.5 CXCL8 ELANE SFTPB
6 respiratory failure 30.4 CXCL8 ELANE SCGB1A1 SFTPB
7 acute respiratory distress syndrome 30.3 CXCL8 ELANE SFTPB
8 interstitial emphysema 30.0 ELANE FLT1
9 bronchitis 29.6 CXCL8 ELANE RNASE3
10 asthma 29.1 CXCL8 ELANE IL1RN ITGAM RNASE3 SCGB1A1
11 pulmonary fibrosis, idiopathic 29.0 CXCL8 ELANE IL1RN SCGB1A1 SFTPB TIMP1
12 pulmonary disease, chronic obstructive 28.9 CXCL8 ELANE RNASE3 SCGB1A1 SFTPB TIMP1
13 borderline personality disorder 11.7
14 pulmonary hypertension, neonatal 11.2
15 multiple personality disorder 11.1
16 pulmonary hypertension 10.8
17 personality disorder 10.7
18 patent ductus arteriosus 1 10.4
19 hypertension, essential 10.4
20 toxicodendron dermatitis 10.4 CXCL8 SELL
21 respiratory distress syndrome in premature infants 10.4
22 respiratory distress syndrome, infant 10.4
23 toxic myocarditis 10.3 CXCL8 SOD1
24 disorganization, mouse, homolog of 10.3
25 paraquat lung 10.3 SCGB1A1 SFTPB
26 cardiac rupture 10.3 CXCL8 ELANE
27 pouchitis 10.3 CXCL8 IL1RN
28 capillary leak syndrome 10.3 CXCL8 ELANE
29 exudative vitreoretinopathy 1 10.3
30 toxic pneumonitis 10.3 SCGB1A1 SFTPB
31 hypoxia 10.3
32 necrotizing fasciitis 10.3 CXCL8 IL1RN
33 cryptogenic organizing pneumonia 10.3 CXCL8 TIMP1
34 cyclic neutropenia 10.3 CXCL8 ELANE
35 arthus reaction 10.2 ELANE SELL
36 pre-eclampsia 10.2
37 bronchiolitis 10.2
38 disease of mental health 10.2
39 mid-dermal elastolysis 10.2 ELANE TIMP1
40 bacterial pneumonia 10.2 CXCL8 ELANE SFTPB
41 adult respiratory distress syndrome 10.2 CXCL8 ELANE SFTPB
42 cerebral palsy 10.2
43 vascular disease 10.2
44 mild pre-eclampsia 10.2 FLT1 SOD1
45 aseptic meningitis 10.2 CXCL8 IL1RN
46 lung giant cell carcinoma 10.2 CXCL8 TIMP1
47 breast cancer 10.2
48 meconium aspiration syndrome 10.2 CXCL8 SCGB1A1 SFTPB
49 pleural tuberculosis 10.2 CXCL8 TIMP1
50 gastroesophageal reflux 10.2

Graphical network of the top 20 diseases related to Bronchopulmonary Dysplasia:



Diseases related to Bronchopulmonary Dysplasia

Symptoms & Phenotypes for Bronchopulmonary Dysplasia

Human phenotypes related to Bronchopulmonary Dysplasia:

60 33 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 emphysema 60 33 hallmark (90%) Very frequent (99-80%) HP:0002097
2 respiratory distress 60 33 hallmark (90%) Very frequent (99-80%) HP:0002098
3 cough 60 33 hallmark (90%) Very frequent (99-80%) HP:0012735
4 premature birth 60 33 hallmark (90%) Very frequent (99-80%) HP:0001622
5 respiratory failure requiring assisted ventilation 60 33 hallmark (90%) Very frequent (99-80%) HP:0004887
6 small for gestational age 60 33 hallmark (90%) Very frequent (99-80%) HP:0001518
7 chronic lung disease 60 33 hallmark (90%) Very frequent (99-80%) HP:0006528
8 hyperoxemia 60 33 hallmark (90%) Very frequent (99-80%) HP:0012419
9 sleep disturbance 60 33 frequent (33%) Frequent (79-30%) HP:0002360
10 exercise intolerance 60 33 frequent (33%) Frequent (79-30%) HP:0003546
11 diaphragmatic paralysis 60 33 frequent (33%) Frequent (79-30%) HP:0006597
12 central apnea 60 33 frequent (33%) Frequent (79-30%) HP:0002871
13 right ventricular hypertrophy 60 33 frequent (33%) Frequent (79-30%) HP:0001667
14 right ventricular failure 60 33 frequent (33%) Frequent (79-30%) HP:0001708
15 wheezing 60 33 frequent (33%) Frequent (79-30%) HP:0030828
16 atelectasis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100750
17 tracheobronchomalacia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002786
18 pulmonary sequestration 60 33 occasional (7.5%) Occasional (29-5%) HP:0100632
19 dyspnea 60 Very frequent (99-80%)
20 functional respiratory abnormality 60 Frequent (79-30%)
21 abnormality of lung morphology 60 Very frequent (99-80%)
22 abnormal respiratory system morphology 60 Frequent (79-30%)

MGI Mouse Phenotypes related to Bronchopulmonary Dysplasia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 ELANE FGF10 FLT1 IL1RN ITGAM RBP4
2 cardiovascular system MP:0005385 9.87 FGF10 FLT1 IL1RN RBP4 SELL SOD1
3 hematopoietic system MP:0005397 9.86 ELANE FGF10 FLT1 IL1RN ITGAM SELL
4 immune system MP:0005387 9.61 ELANE FGF10 FLT1 IL1RN ITGAM SCGB1A1
5 neoplasm MP:0002006 9.02 ELANE SCGB1A1 SELL SOD1 TIMP1

Drugs & Therapeutics for Bronchopulmonary Dysplasia

PubMedHealth treatment related to Bronchopulmonary Dysplasia: 64

If your doctor thinks you're going to give birth too early, he or she may give you injections of a corticosteroid medicine.The medicine can speed up surfactant production in your baby. Surfactant is a liquid that coats the inside of the lungs. It helps keep the lungs open so your infant can breathe in air once he or she is born.Corticosteroids also can help your baby's lungs, brain, and kidneys develop more quickly while he or she is in the womb.Premature babies who have very low birth weights also might be given corticosteroids within the first few days of birth. Doctors sometimes prescribe inhaled nitric oxide shortly after birth for babies who have very low birth weights. This treatment can help improve the babies' lung function.These preventive measures may help reduce infants' risk of respiratory distress syndrome (RDS), which can lead to BPD.

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
RespiGam 19 MedImmune January 1996

Drugs for Bronchopulmonary Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51333-22-3 5281004 63006
2 Beractant Approved Phase 4,Phase 2,Phase 3 108778-82-1
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
5 Poractant alfa Approved Phase 4,Phase 2,Phase 3,Not Applicable 129069-19-8
6
Caffeine Approved Phase 4,Phase 3,Not Applicable 58-08-2 2519
7
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
8
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 447043 55185
9
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
10
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57-83-0 5994
11
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
12
Remifentanil Approved Phase 4,Phase 1,Phase 2 132875-61-7 60815
13
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
14
Nifedipine Approved Phase 4 21829-25-4 4485
15
Labetalol Approved Phase 4 36894-69-6 3869
16
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 7440-70-2 271
17
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
18 Olive Phase 4,Phase 3,Not Applicable
19 Soy Bean Phase 4,Phase 3,Not Applicable
20 Omega 3 Fatty Acid Phase 4,Phase 3,Not Applicable
21 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Pulmonary Surfactants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Tocolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
36 Antiemetics Phase 4,Phase 3,Phase 2
37 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
39
protease inhibitors Phase 4,Phase 3,Phase 2
40 BB 1101 Phase 4,Phase 3,Phase 2
41 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable
42 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
43 Purinergic P1 Receptor Antagonists Phase 4,Phase 3,Not Applicable
44 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Adrenergic Agonists Phase 4,Not Applicable
48 Adrenergic beta-2 Receptor Agonists Phase 4,Not Applicable
49 Albuterol Phase 4,Not Applicable
50 Adrenergic beta-Agonists Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 440)
# Name Status NCT ID Phase Drugs
1 Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide Unknown status NCT02853253 Phase 4
2 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
3 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
4 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
5 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
6 Preterm Infant Inhaled Albuterol Dosing Completed NCT02447250 Phase 4 Varied albuterol dose response
7 Azithromycin in the Prevention of Lung Injury in Premature Newborn Completed NCT03485703 Phase 4 Azithromycin;Placebo
8 Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis Completed NCT02959229 Phase 4 Lactoferrin;Placebo (for Lactoferrin)
9 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
10 A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome Completed NCT00201643 Phase 4 Betamethasone or Dexamethasone (2nd course of ACS);Placebo
11 Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Completed NCT00331695 Phase 4 17 alpha-hydroxyprogesterones caproate
12 Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part IV Completed NCT01604447 Phase 4
13 Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates Completed NCT01403623 Phase 4
14 Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia. Recruiting NCT03521063 Phase 4 Budesonide;Poractant Alfa;Saline
15 OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP Recruiting NCT02140580 Phase 4
16 Early Caffeine in Preterm Neonates Recruiting NCT03086473 Phase 4 Caffeine Citrate;Placebo (Normal Saline)
17 Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor Recruiting NCT02430233 Phase 4 micronized progesterone 400 mg (Utrogestan)
18 Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome Recruiting NCT02164734 Phase 4 remifentanil
19 Chronic Hypertension and Pregnancy (CHAP) Project Recruiting NCT02299414 Phase 4 Anti-hypertensive therapy
20 Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4 Curosurf
21 Intratracheal Budesonide/Surfactant Prevents BPD Not yet recruiting NCT03275415 Phase 4 budesonide;Saline
22 Personalized vs Standardized PN for Preterm Infants >1250g Not yet recruiting NCT03693287 Phase 4 Standardized-parenteral nutrition (S-PN);Personalized-parenteral nutrition (P-PN)
23 Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
24 Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis Unknown status NCT01652118 Phase 3 clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;Saline
25 Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia Unknown status NCT01022580 Phase 3 Infasurf surfactant (ONY, Inc.)
26 Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease Unknown status NCT01721655 Phase 2, Phase 3 Spironolactone;Placebo
27 Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane Unknown status NCT01503606 Phase 3 Cefazolin;Clarithromycin;Cefazolin;Clarithromycin
28 Cysteine Supplementation in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
29 Prophylactic Acetaminophen for Prevention Intraventricular Hemorrhage in Premature Infants Unknown status NCT03024814 Phase 3 Acetaminophen;Dextrose 5
30 Pessary as Adjunctive Therapy to Cerclage for the Prevention of Preterm Birth Unknown status NCT02678026 Phase 3
31 Cerclage for Singletons With Short Cervix Without Prior Preterm Birth Unknown status NCT02716922 Phase 3
32 A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders Unknown status NCT02336243 Phase 3
33 Modulation of the Intestinal Flora With the Probiotic VIVOMIXX™ in Pregnant Women at Risk of Metabolic Complications Unknown status NCT02768818 Phase 3
34 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Completed NCT00931632 Phase 3 Inhaled Nitric Oxide;Placebo
35 Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia Completed NCT01035190 Phase 3 Budesonide
36 PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates Completed NCT00623740 Phase 3 hydrocortisone;placebo
37 Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia Completed NCT01503801 Phase 2, Phase 3 Nitric Oxide
38 Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia Completed NCT00004785 Phase 3 dexamethasone;methylprednisolone
39 Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV) Completed NCT00433212 Phase 3
40 Inhaled Beclomethasone to Prevent Chronic Lung Disease Completed NCT00000576 Phase 3 beclomethasone
41 Post-hospitalization Nursing Effectiveness (PHONE) Study Completed NCT00314431 Phase 3
42 Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome Completed NCT01203358 Phase 2, Phase 3 Exosurf;Survanta
43 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide Completed NCT00569530 Phase 3 Infasurf (ONY Inc.);Sham
44 Inhaled NO in Prevention of Chronic Lung Disease Completed NCT00000548 Phase 3
45 Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Completed NCT00006401 Phase 3 iNO
46 Surfactant Positive Airway Pressure and Pulse Oximetry Trial Completed NCT00233324 Phase 3 Surfactant;Supplemental oxygen with target saturation of 85 to 89%;Supplemental oxygen with target saturation of 91 to 95%
47 Randomized Trial of Nasal Continuous Positive Airway Pressure or Synchronized Nasal Ventilation in Premature Infants. Completed NCT00188968 Phase 3
48 L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia Completed NCT01306227 Phase 3 L-Thyroxine;water
49 Vitamin D Supplementation for Extremely Preterm Infants Completed NCT01600430 Phase 2, Phase 3
50 High Frequency Ventilation in Premature Infants (HIFI) Completed NCT00000567 Phase 3

Search NIH Clinical Center for Bronchopulmonary Dysplasia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchopulmonary Dysplasia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchopulmonary Dysplasia:
PNEUMOSTEM, cord blood-derived mesenchymal stem cells for bronchopulmonary dysplasia

Genetic Tests for Bronchopulmonary Dysplasia

Anatomical Context for Bronchopulmonary Dysplasia

MalaCards organs/tissues related to Bronchopulmonary Dysplasia:

42
Lung, Brain, Cervix, Bone, Breast, Endothelial, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchopulmonary Dysplasia:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Alveoli Alveolar Epithelial Type 1 Cells Affected by disease, potential therapeutic candidate
2 Lung Alveoli Alveolar Epithelial Type 2 Cells Affected by disease, potential therapeutic candidate
3 Lung Pulmonary Capillary Plexus Affected by disease

Publications for Bronchopulmonary Dysplasia

Articles related to Bronchopulmonary Dysplasia:

(show top 50) (show all 2366)
# Title Authors Year
1
Bronchopulmonary dysplasia in very preterm infants: Outcome up to preschool age, in a single center of Austria. ( 30793436 )
2019
2
Genetic Strain and Sex Differences in a Hyperoxia-Induced Mouse Model of Varying Severity of Bronchopulmonary Dysplasia. ( 30794808 )
2019
3
Enteral iron supplementation, red blood cell transfusion, and risk of bronchopulmonary dysplasia in very-low-birth-weight infants. ( 30801736 )
2019
4
Changing expression profiles of mRNA, lncRNA, circRNA, and miRNA in lung tissue reveal the pathophysiological of bronchopulmonary dysplasia (BPD) in mouse model. ( 30802330 )
2019
5
EXPRESS: Sildenafil for bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis. ( 30803328 )
2019
6
Thioredoxin Reductase-1 Inhibition Augments Endogenous Glutathione-Dependent Antioxidant Responses in Experimental Bronchopulmonary Dysplasia. ( 30805084 )
2019
7
Oxidative Stress and Bronchopulmonary Dysplasia: Evidences From Microbiomics, Metabolomics, and Proteomics. ( 30815432 )
2019
8
NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants. ( 30820654 )
2019
9
Positive end-expiratory pressure for preterm infants requiring conventional mechanical ventilation for respiratory distress syndrome or bronchopulmonary dysplasia. ( 30820939 )
2019
10
Postnatal nutritional deficit is an independent predictor of bronchopulmonary dysplasia among extremely premature infants born at or less than 28 weeks gestation. ( 30825742 )
2019
11
Preeclampsia and risk of developing bronchopulmonary dysplasia in very preterm neonates. ( 30825928 )
2019
12
Human amnion cells for the prevention of bronchopulmonary dysplasia: a protocol for a phase I dose escalation study. ( 30826799 )
2019
13
Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics. ( 30830433 )
2019
14
Is Endocan a Novel Diagnostic Marker for the Severity of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants? ( 30833192 )
2019
15
Progress needed in bronchopulmonary dysplasia. ( 30833220 )
2019
16
Commentary on "Oxygen desaturations in the early neonatal period predict development of bronchopulmonary dysplasia" by Fairchild et al. ( 30836376 )
2019
17
Intercenter variability and factors associated with survival without bronchopulmonary dysplasia in extremely preterm newborns. ( 30836798 )
2019
18
Oral Feeding in Neonates with Bronchopulmonary Dysplasia. ( 30838533 )
2019
19
Exploring clinical, echocardiographic and molecular biomarkers to predict bronchopulmonary dysplasia. ( 30840669 )
2019
20
Bronchopulmonary Dysplasia: The Importance Of Physical Exercise. ( 30846204 )
2019
21
Effect of Montelukast on Bronchopulmonary Dysplasia (BPD) and Related Mechanisms. ( 30862773 )
2019
22
Designing a better definition of bronchopulmonary dysplasia. ( 30864236 )
2019
23
Acute Vasoreactivity Testing during Cardiac Catheterization of Neonates with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension. ( 30871795 )
2019
24
Systemic artery-pulmonary artery fistulae of adult bronchopulmonary dysplasia characterized with dynamic CT angiography and multiphase 3D-volumetric reconstruction: a case report. ( 30881878 )
2019
25
Ten-year-old children with a history of bronchopulmonary dysplasia have regional abnormalities in ventilation perfusion matching. ( 30887678 )
2019
26
Effect of Sustained Inflations vs Intermittent Positive Pressure Ventilation on Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants: The SAIL Randomized Clinical Trial. ( 30912836 )
2019
27
Excessive activation of NMDA receptor inhibits the protective effect of endogenous bone marrow MSCs on promoting alveolarization in bronchopulmonary dysplasia. ( 30917030 )
2019
28
Impact of a protocol-driven unified service for neonates with bronchopulmonary dysplasia. ( 30918896 )
2019
29
The impact of inhaled bronchodilators on bronchopulmonary dysplasia: a nonrandomized comparison from the NEuroSIS trial. ( 30922128 )
2019
30
Revealing hub pathway cross-talk for premature newborns with bronchopulmonary dysplasia by the integration of pathway analysis and Monte Carlo Cross-Validation. ( 30930971 )
2019
31
Prolonged non-invasive ventilation in extremely low birth weight preterm infants is associated with bronchopulmonary dysplasia. ( 30932902 )
2019
32
Screening Echocardiography and Brain Natriuretic Peptide Levels Predict Late Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia. ( 30937503 )
2019
33
Mortality in infants with bronchopulmonary dysplasia: Data from cardiac catheterization. ( 30938937 )
2019
34
The BIT:S (Bronchopulmonary Dysplasia Interdisciplinary Team: Severe) Initiative at Women and Infants Hospital of Rhode Island. ( 30943667 )
2019
35
Identifying and treating intrinsic PEEP in infants with severe bronchopulmonary dysplasia. ( 30950245 )
2019
36
Development of an ex vivo respiratory pediatric model of bronchopulmonary dysplasia for aerosol deposition studies. ( 30952897 )
2019
37
Influence of prevention of caffeine citrate on cytokine profile and bronchopulmonary dysplasia in preterm infants with apnea. ( 30961342 )
2019
38
Long-term effects of postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia: Balancing the risks and benefits. ( 30962159 )
2019
39
Infants with evolving bronchopulmonary dysplasia demonstrate monocyte-specific expression of IL-1 in tracheal aspirates. ( 30969811 )
2019
40
Bronchopulmonary Dysplasia: 50 Years after the Original Description. ( 30974430 )
2019
41
Home Oxygen and 2-Year Outcomes of Preterm Infants With Bronchopulmonary Dysplasia. ( 30975699 )
2019
42
Bronchopulmonary Dysplasia and Pulmonary Outcomes of Prematurity. ( 30986315 )
2019
43
Home Oxygen Use for Preterm Infants with Bronchopulmonary Dysplasia in California. ( 30987778 )
2019
44
The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants: An Evidence-Based Approach. ( 30995069 )
2019
45
Association of Center-Specific Patient Volumes and Early Respiratory Management Practices with Death and Bronchopulmonary Dysplasia in Preterm Infants. ( 31005279 )
2019
46
Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia. ( 31010561 )
2019
47
Respiratory severity score as a predictive factor for severe bronchopulmonary dysplasia or death in extremely preterm infants. ( 31014304 )
2019
48
Corticosteroids in bronchopulmonary dysplasia. ( 31017360 )
2019
49
Postnatal nutritional deficit is an independent predictor of bronchopulmonary dysplasia among extremely premature infants born at or <28 weeks gestation: Some methodological issues. ( 31029543 )
2019
50
Neonatal hematological parameters and the risk of moderate-severe bronchopulmonary dysplasia in extremely premature infants. ( 31039810 )
2019

Variations for Bronchopulmonary Dysplasia

Expression for Bronchopulmonary Dysplasia

Search GEO for disease gene expression data for Bronchopulmonary Dysplasia.

Pathways for Bronchopulmonary Dysplasia

GO Terms for Bronchopulmonary Dysplasia

Cellular components related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.8 ELANE IL1RN ITGAM RBP4 SCGB1A1 SOD1
2 extracellular region GO:0005576 9.7 CXCL8 ELANE FGF10 FLT1 IL1RN RBP4
3 extracellular space GO:0005615 9.4 CXCL8 ELANE FGF10 FLT1 IL1RN ITGAM
4 secretory granule GO:0030141 9.33 ELANE SCGB1A1 SOD1

Biological processes related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.8 ELANE ITGAM RNASE3 SELL
2 regulation of signaling receptor activity GO:0010469 9.73 CXCL8 FGF10 IL1RN TIMP1
3 leukocyte migration GO:0050900 9.7 ELANE ITGAM SELL
4 response to lipopolysaccharide GO:0032496 9.65 ELANE FGF10 SCGB1A1
5 chemotaxis GO:0006935 9.63 CXCL8 FGF10 FLT1
6 negative regulation of apoptotic process GO:0043066 9.54 SOD1 TIMP1
7 blood vessel morphogenesis GO:0048514 9.51 FGF10 FLT1
8 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.4 FGF10 FLT1
9 embryonic digestive tract development GO:0048566 9.37 CXCL8 FGF10
10 response to organic substance GO:0010033 9.33 SCGB1A1 SOD1 TIMP1
11 positive regulation of superoxide anion generation GO:0032930 9.32 ITGAM SOD1
12 induction of positive chemotaxis GO:0050930 9.26 CXCL8 FGF10
13 cytokine-mediated signaling pathway GO:0019221 9.26 CXCL8 IL1RN ITGAM TIMP1
14 female genitalia morphogenesis GO:0048807 8.62 FGF10 RBP4

Molecular functions related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.33 CXCL8 IL1RN TIMP1
2 heparin binding GO:0008201 9.13 ELANE FGF10 SELL
3 protease binding GO:0002020 8.8 ELANE SELL TIMP1

Sources for Bronchopulmonary Dysplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....